LEO eyeing 2021 US launch for eczema drug tralokinumab

LEO Pharma is gearing up to launch its eczema drug tralokinumab next year after submitting a filing to the FDA, as it bids to take on Sanofi’s class rival Dupixent. 

Eyeing Dupixent’s territory, Leo Pharma files tralokinumab i...

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanof

NICE rejects NHS funding Sanofi/Regeneron's Dupixent in asth...

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence.

Lilly swoops on Dermira to claim Dupixent rival

Regeneron/Sanofi get EU okay for Dupixent in “asthma of the ...

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum